



Dw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/767,784
	Filing Date	January 29, 2004
	First Named Inventor	Galley
	Art Unit	1614
	Examiner Name	Ward, Paul V
Total Number of Pages in This Submission	21453	


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): _____
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Kimberly J. Prior	
Signature		
Date	06/05/2006	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Kimberly J. Prior	
Signature		Date
		06/05/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

240069

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Galley, et al.

Group: 1614

Serial No. 10/767,784, filed January 29, 2004
(Ref. No. 21453)

Examiner: Ward, Paul V.

For: **MALONAMIDE DERIVATIVES**

RESPONSE TO RESTRICTION REQUIREMENT

Nutley, New Jersey 07110

Date: June 5, 2006

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This election is filed in response to the Restriction Requirement issued May 5, 2006, in connection with the above-identified patent application. A response to this Restriction Requirement is due June 5, 2006. Applicants respectfully request consideration of the following remarks.

Claims 1 to 24 are pending. The claims have been restricted to the following forty-two groups.

- I. The compounds according to claim 1 of formula IA, wherein C is phenyl.
- II. The compounds according to claim 1 of formula IA, wherein C is pyridinyl.
- III. The compounds according to claim 1 of formula IA, wherein C is furanyl or tetrahydrofuranyl.

- IV. The compounds according to claim 1 of formula IA, wherein C is benzo[b]thiophenyl.
- V. The compounds according to claim 1 of formula IA, wherein C is tetrahydronaphthyl.
- VI. The compounds according to claim 1 of formula IA, wherein C is indanyl.
- VII. The compounds according to claim 1 of formula IA, wherein C is 2,2,dimethyl-[1,3]dioxolanyl.
- VIII. The compounds according to claim 1 of formula IB, wherein C is phenyl.
- IX. The compounds according to claim 1 of formula IB, wherein C is pyridinyl.
- X. The compounds according to claim 1 of formula IB, wherein C is furanyl or tetrahydrofuranyl.
- XI. The compounds according to claim 1 of formula IB, wherein C is benzo[b]thiophenyl.
- XII. The compounds according to claim 1 of formula IB, wherein C is tetrahydronaphthyl.
- XIII. The compounds according to claim 1 of formula IB, wherein C is indanyl.
- XIV. The compounds according to claim 1 of formula IB, wherein C is 2,2,dimethyl-[1,3]dioxolanyl.
- XV. The process for preparing a compound formula IA according to claim 22, wherein C is phenyl.
- XVI. The process for preparing a compound formula IA according to claim 22, wherein C is pyridinyl.
- XVII. The process for preparing a compound formula IA according to claim 22, wherein C is furanyl or tetrahydrofuranyl
- XVIII. The process for preparing a compound formula IA according to claim 22, wherein C is benzo[b]thiophenyl.
- XIX. The process for preparing a compound formula IA according to claim 22, wherein C is tetrahydronaphthyl.
- XX. The process for preparing a compound formula IA according to claim 22, wherein C is indanyl.

- XXI. The process for preparing a compound formula IA according to claim 22, wherein C is 2,2, dimethyl-[1,3] dioxolanyl.
- XXII. The process for preparing a compound formula IB according to claim 23, wherein C is phenyl.
- XXIII. The process for preparing a compound formula IB according to claim 23, wherein C is pyridinyl.
- XXIV. The process for preparing a compound formula IB according to claim 23, wherein C is furanyl or tetrahydrofuranyl.
- XXV. The process for preparing a compound formula IB according to claim 23, wherein C is benzo[b]thiophenyl.
- XXVI. The process for preparing a compound formula IB according to claim 23, wherein C is tetrahydronaphthyl.
- XXVII. The process for preparing a compound formula IB according to claim 23, wherein C is indanyl.
- XXVIII. The process for preparing a compound formula IB according to claim 23, wherein C is 2,2, dimethyl-[1,3]dioxolanyl.
- XXIX. The method of treating according to claims 20-21 of formula IA, wherein C is phenyl.
- XXX. The method of treating according to claims 20-21 of formula IA, wherein C is pyridinyl.
- XXXI. The method of treating according to claims 20-21 of formula IA, wherein C is furanyl or tetrahydrofuranyl.
- XXXII. The method of treating according to claims 20-21 of formula IA, wherein C is benzo[b]thiophenyl.
- XXXIII. The method of treating according to claims 20-21 of formula IA, wherein C is tetrahydronaphthyl.
- XXXIV. The method of treating according to claims 20-21 of formula IA, wherein C is indanyl.
- XXXV. The method of treating according to claims 20-21 of formula IA, wherein C is 2,2, dimethyl-[1,3] dioxolanyl.
- XXXVI. The method of treating according to claims 20-21 of formula IB, wherein C is phenyl.

XXXVII. The method of treating according to claims 20-21 of formula IB, wherein C is pyridinyl.

XXXVIII. The method of treating according to claims 20-21 of formula IB, wherein C is furanyl or tetrahydrofuranyl.


XXXIX. The method of treating according to claims 20-21 of formula IB, wherein C is benzo[b]thiophenyl.

XL. The method of treating according to claims 20-21 of formula IB, wherein C is tetrahydronaphthyl.

XLI. The method of treating according to claims 20-21 of formula IB, wherein C is indanyl.

XLII. The method of treating according to claims 20-21 of formula IB, wherein C is 2,2-dimethyl-[1,3] dioxolanyl.

Applicants hereby elect with traverse Group I, claims 1 to 6, 9 to 14, and 17 to 19, directed to compounds of formula IA wherein C is phenyl and compositions containing them, and the species N-(5-Benzoyl-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-N'-(3,5-difluorobenzyl)-2-methyl-malonamide (Example 14), having the following structure:



Claims 1 to 3, 11, 12, and 17 to 19 read on the elected species.

The requirements are traversed for the following reasons. Upon an election of species, M.P.E.P. § 803.02 states that if no prior art is found that anticipates or renders obvious the elected species, search and examination of the claims will be extended to the extent necessary to

Serial No. 10/767,784
Filed: January 29, 2004

determine patentability of the generic claim. Thus, Applicants understand that if no art is found which anticipates or renders obvious the elected species, search and examination will be expanded to the extent necessary to determine patentability of the generic claim or at least to the extent necessary to determine patentability of Group I.


Further, method claims 20 to 24 have been restricted from the product claims as Groups XV to XLII. In accordance with M.P.E.P. § 821.04, Applicants understand that upon the finding of an allowable compound claim, those claims of Groups XV to XLII having all of the limitations of the allowable product claim will be rejoined and examined on the merits.

The foregoing amendment is fully responsive to the Restriction Requirement issued May 5, 2006. Early and favorable consideration is earnestly solicited.

No additional fees are believed due. However, the Director is hereby authorized to charge any deficit, or credit any overpayment, to Deposit Account No. 08-2525.

If the Examiner believes there are other issues that can be resolved by telephone interview, or that there are any informalities remaining in the application which may be corrected by Examiner's Amendment, a telephone call to the undersigned attorney is respectfully solicited.

Respectfully submitted,



Kimberly J. Prior
Attorney for Applicant(s)
(Reg. No. 41,483)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6208
Telefax: (973) 235-2363

236237